Lateral flow assays (LFA) currently used for point-of-care Covid-19 diagnostics suffer from low sensitivity and misdiagnose significant proportion of cases. However, more sensitive PCR and ELISA techniques are too time consuming or complex to be used for rapid results at point-of-care. The automated multiplex platform developed in the project will address this limitation and offer a low cost rapid 20-minute diagnostic test with the sensitivity 1000 times higher than that of LFA. The outcome of this project will be a market ready Canadian-made device that can be used for rapid diagnosis of Covid-19 infections.